Enanta Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ENTA, Enanta Pharmaceuticals Inc, priceseries

Enanta Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
66.21
Close
67.51
High
68.51
Low
66.18
Previous Close
67.04
Daily Price Gain
0.47
YTD High
75.28
YTD High Date
Jan 3, 2022
YTD Low
54.42
YTD Low Date
Jan 24, 2022
YTD Price Change
-6.60
YTD Gain
-8.91%
52 Week High
102.00
52 Week High Date
Nov 5, 2021
52 Week Low
40.37
52 Week Low Date
Jul 15, 2021
52 Week Price Change
17.62
52 Week Gain
35.32%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 12. 2017
31.15
Jul 7. 2017
36.13
18 Trading Days
15.98%
Link
LONG
Aug 24. 2017
39.31
Sep 12. 2017
41.87
12 Trading Days
6.51%
Link
LONG
Sep 27. 2017
44.53
Oct 16. 2017
47.62
13 Trading Days
6.94%
Link
LONG
Jan 16. 2018
62.76
Feb 8. 2018
83.52
17 Trading Days
33.08%
Link
LONG
Jun 29. 2018
115.90
Jul 16. 2018
121.72
10 Trading Days
5.02%
Link
LONG
Jan 30. 2019
79.02
Mar 6. 2019
99.92
24 Trading Days
26.45%
Link
LONG
Jan 29. 2021
48.06
Feb 12. 2021
51.69
10 Trading Days
7.56%
Link
LONG
Aug 19. 2021
48.58
Sep 9. 2021
56.20
14 Trading Days
15.68%
Link
LONG
Oct 6. 2021
61.20
Nov 15. 2021
89.89
28 Trading Days
46.88%
Link
Company Information
Stock Symbol
ENTA
Exchange
NasdaqGS
Company URL
http://www.enanta.com
Company Phone
617 607 0800
CEO
Jay R. Luly
Headquarters
Massachusetts
Business Address
500 ARSENAL STREET, WATERTOWN, MA 02472
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001177648
About

Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It focuses on the following disease targets: Hepatitis C virus, Hepatitis B virus, Non-alcoholic Steatohepatitis, and Respiratory syncytial virus. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Description

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading